TORONTO — David Pidduck will step down from his role as MediPharm Labs Corp.’s chief executive officer effective January 23. The Board of Directors has appointed Greg Hunter, the company’s chief financial officer interim chief executive officer while it evaluates long‑term leadership plans. Hunter will continue to serve as CFO.
Pidduck will continue to serve on the board to ensure a seamless transition.
Since assuming the CFO role in February 2021, Hunter has implemented meaningful cost‑reduction initiatives and strengthened financial and operational controls. He has also been deeply involved in commercial strategy, working closely with the sales, marketing, and product teams to enhance pricing, support key customer programs, negotiate improved commercial terms, and ensure manufacturing and supply capabilities align with market demand.
In addition to his financial background, Hunter also brings broad commercial, operational, and general management experience, gained over more than 20 years in cross-functional leadership roles at global Fortune 500 organizations such as Johnson & Johnson and Baxter, as well as private equity portfolio companies.
Related Articles:
